EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEAwmm2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AMLInvivoscribe Marketing2024-05-07T17:44:56-07:00May 8th, 2024|2024 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTAInvivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer ResearchInvivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in JapanInvivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in ChinaInvivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)Invivoscribe Marketing2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AMLwmm2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases| Read more
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AMLInvivoscribe Marketing2022-08-16T20:08:13-07:00August 16th, 2022|2022 Press Releases, Press Releases| Read more
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicinewmm2022-05-09T17:27:05-07:00May 9th, 2022|2022 Press Releases, Press Releases| Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline UseInvivoscribe Marketing2021-09-02T16:53:40-07:00September 2nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in ChinaInvivoscribe Marketing2021-07-22T17:27:56-07:00July 22nd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune Systemwmm2021-06-24T18:20:34-07:00June 24th, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and Chinawmm2021-06-03T20:36:18-07:00June 3rd, 2021|2021 Press Releases, Press Releases| Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United StatesInvivoscribe Marketing2021-02-26T19:09:52-08:00May 19th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases| Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTAInvivoscribe Marketing2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic MalignanciesInvivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2021-02-26T19:10:54-08:00January 3rd, 2019|2019 Press Releases, Press Releases| Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in JapanInvivoscribe Marketing2021-02-26T19:11:02-08:00November 29th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for QuizartinibInvivoscribe Marketing2022-09-23T16:52:06-07:00November 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in JapanInvivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|2018 Press Releases, Press Releases| Read more